Prudential Financial Inc. grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 433,670 shares of the company’s stock after purchasing an additional 7,810 shares during the period. Prudential Financial Inc. owned approximately 0.91% of Charles River Laboratories International worth $46,844,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bridgewater Associates LP purchased a new position in shares of Charles River Laboratories International during the 2nd quarter valued at $679,000. American Century Companies Inc. purchased a new position in shares of Charles River Laboratories International during the 2nd quarter valued at $292,000. Northern Trust Corp grew its position in shares of Charles River Laboratories International by 1.5% during the 2nd quarter. Northern Trust Corp now owns 436,860 shares of the company’s stock valued at $44,188,000 after purchasing an additional 6,304 shares in the last quarter. Alps Advisors Inc. grew its position in shares of Charles River Laboratories International by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,350 shares of the company’s stock valued at $541,000 after purchasing an additional 14 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Charles River Laboratories International by 14.4% in the second quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the company’s stock worth $123,391,000 after acquiring an additional 153,374 shares in the last quarter. Hedge funds and other institutional investors own 97.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Stake Lifted by Prudential Financial Inc.” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/12/charles-river-laboratories-international-inc-crl-stake-lifted-by-prudential-financial-inc.html.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) opened at C$102.12 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.49 and a current ratio of 1.88. Charles River Laboratories International, Inc. has a 1 year low of C$69.51 and a 1 year high of C$119.05. The stock has a market cap of $4,836.61, a PE ratio of 20.06, a price-to-earnings-growth ratio of 1.64 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The company reported C$1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of C$1.22 by C$0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business had revenue of C$464.23 million during the quarter, compared to analyst estimates of C$458.93 million. During the same period in the prior year, the business posted $1.18 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. equities research analysts anticipate that Charles River Laboratories International, Inc. will post 5.12 EPS for the current year.

In other Charles River Laboratories International news, insider William D. Barbo sold 4,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of C$99.91, for a total transaction of C$399,640.00. Following the completion of the sale, the insider now directly owns 20,424 shares in the company, valued at C$2,040,561.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of C$67.10, for a total transaction of C$171,239.20. Following the sale, the insider now owns 11,671 shares of the company’s stock, valued at C$783,124.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 10,500 shares of company stock valued at $2,885 and have sold 18,699 shares valued at $1,892,393. Corporate insiders own 2.20% of the company’s stock.

Several research analysts recently issued reports on the stock. ValuEngine lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday. Bank of America Corporation cut their target price on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Tuesday, October 24th. Credit Suisse Group reiterated a “neutral” rating and issued a $112.00 target price (up from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Finally, Jefferies Group LLC upped their target price on shares of Charles River Laboratories International from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories International has a consensus rating of “Buy” and an average target price of C$105.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.